Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
RGD |
Identification of liver proteins and their roles associated with carbon tetrachloride-induced hepatotoxicity.
|
21138988 |
2011 |
Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
CTD_human |
Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury.
|
18666253 |
2008 |
Chemical and Drug Induced Liver Injury
|
0.500 |
Biomarker
|
disease |
CTD_human |
Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity.
|
17465707 |
2007 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we investigated the relationship of three GSTs polymorphisms (GSTT1 deletion, GSTM1 deletion, GSTP1 rs1695) as well as GSTP1 promoter region DNA methylation and HCC risk with a particular focus on the interaction with OCPs exposure among 90 HCC cases and 99 controls in a Chinese population.
|
31731000 |
2020 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The combination of higher CG methylation levels of <i>LMO2_E148, IL10_P325</i>, and <i>GSTM1_P266</i> corresponded to the highest risk of asthma by 43.48%, compared to other combinations (16.67-23.08%) in the 3-way multi-factor dimensionality reduction (MDR) analysis.
|
31214241 |
2019 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the impact of GSTM1 null genotype on bladder cancer patients' outcome.
|
31646988 |
2019 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the association of serum organochlorine pesticides (OCPs) and organophosphorus pesticides (OPs) levels and GSTM1/GSTT1 gene polymorphism with bladder cancer (BC).
|
31009110 |
2019 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the association of serum organochlorine pesticides (OCPs) and organophosphorus pesticides (OPs) levels and GSTM1/GSTT1 gene polymorphism with bladder cancer (BC).
|
31009110 |
2019 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the impact of GSTM1 null genotype on bladder cancer patients' outcome.
|
31646988 |
2019 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, patients with combined GSTM1-null/GSTT1-null/GSTA1 low-activity/GSTP1-variant genotype showed 2.71-fold increased risk of developing CRC (p = 0.037).
|
30694518 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Separate or combination of GSTM1 and GSTT1 null genotypes (GST gene) were associated with T2DM.
|
28548478 |
2019 |
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, GSTM1 null genotype was also significantly correlated with elevated individual susceptibility to leukemia in East Asians.
|
30659796 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we show the effects of a single dose of Atremorine (5 g, p. o.) on plasma dopamine (DA) response and brain function in PD (n = 183) and the influence that pathogenic (<i>LRRK2</i>), metabolic (<i>CYP2D5, CYP2C9, CYP2C19, CYP3A5, NAT2</i>), transporter (<i>ABCB1</i>), pleiotropic (<i>APOE</i>), and detoxifying genes (<i>CYP1B1, GSTT1, GSTP1, GSTM1, SOD2</i>) involved in the pharmacogenetic network exerts on Atremorine-induced DA response.
|
31559607 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings support the hypothesis that certain polymorphisms in genes involved in DNA-repair and carriers of GSTM1 deletion have an increased risk of lung cancer in never-smokers exposed to residential radon.
|
31446980 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As the relationship between copy number variation and gene expression of GSTM1 in CaP remains unexplored, this study analyzed GSTM1 gene expression and/or dosage effect on CaP risk and aggressiveness.
|
30595465 |
2019 |
Drug-Induced Liver Disease
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Previous studies suggest that individuals who are homozygous-null at the GSTM1 or GSTT1 locus may have an increased risk of environmentally related cancers and drug-induced hepatotoxicity.
|
30471640 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro, Transwell and doxorubicin (DOX)-induced apoptosis assays revealed that GSTM1 showed opposite functions in different HCC cell lines with varied TP53 genotype statuses.
|
31605953 |
2019 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The pooled analysis showed that both GSTM1 null genotypes (OR = 1.37, 95% CI = 1.18-1.59) and GSTT1 null genotypes (OR = 1.43, 95% CI = 1.23-1.66) increased the risk of HCC.
|
30976200 |
2019 |
Asthma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Carriers of GSTM1/T1 null and GSTP1 val genotypes were more susceptible to indoor air pollution exposures, having a higher risk of asthma and lung function deficits.
|
29557517 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggested that GSTM1-null genotype is associated with an increased bladder cancer risk in the Chinese individuals.
|
30539835 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the GSTM1-null, GSTT1-null and dual-null GSTM1-GSTT1 genotypes might be associated with the onset of bladder cancer, but additional genetic-epidemiological studies should be conducted to explore this association further.
|
30419877 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
With regard to BC, an overall odds ratio (OR) of 2.07 [95% confidence interval (CI): 1.38-3.09] for those with GSTM1 and an OR of 2.07 (95% CI: 1.38-3.09) for those with GSTT1 null genotype were reported when exposed to polycyclic aromatic hydrocarbons (PAHs).
|
28403014 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The common deletion of the glutathione S-transferase Mu 1 (GSTM1) gene in humans has been shown to be involved in xenobiotic metabolism and associated with bladder cancer.
|
29695243 |
2018 |
Bladder Neoplasm
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggested that GSTM1-null genotype is associated with an increased bladder cancer risk in the Chinese individuals.
|
30539835 |
2018 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
With regard to BC, an overall odds ratio (OR) of 2.07 [95% confidence interval (CI): 1.38-3.09] for those with GSTM1 and an OR of 2.07 (95% CI: 1.38-3.09) for those with GSTT1 null genotype were reported when exposed to polycyclic aromatic hydrocarbons (PAHs).
|
28403014 |
2018 |